ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1671
0,00%
Bitcoin
68.731,25
0,29%
Brent Oil
81,965
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Talis Biomedical Corporation (TLIS)

  7. Talis Biomedical Corporation (TLIS) Notícias

TLIS

Talis Biomedical (TLIS)

Talis Biomedical Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TLIS
DataHoraFonteTítuloCódigoCompanhia
08/05/202409:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TLISTalis Biomedical Corporation
26/01/202418:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TLISTalis Biomedical Corporation
14/11/202310:00GlobeNewswire Inc.Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashNASDAQ:TLISTalis Biomedical Corporation
10/08/202318:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TLISTalis Biomedical Corporation
10/08/202317:05GlobeNewswire Inc.Talis Biomedical Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:TLISTalis Biomedical Corporation
03/08/202309:00GlobeNewswire Inc.Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023NASDAQ:TLISTalis Biomedical Corporation
02/08/202309:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TLISTalis Biomedical Corporation
02/08/202309:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TLISTalis Biomedical Corporation
02/08/202309:00GlobeNewswire Inc.Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)NASDAQ:TLISTalis Biomedical Corporation
27/07/202309:00GlobeNewswire Inc.New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product MenuNASDAQ:TLISTalis Biomedical Corporation
24/07/202309:00GlobeNewswire Inc.Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:TLISTalis Biomedical Corporation
05/07/202309:00GlobeNewswire Inc.Talis Biomedical Announces 1-for-15 Reverse Stock SplitNASDAQ:TLISTalis Biomedical Corporation
13/06/202317:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TLISTalis Biomedical Corporation
09/06/202317:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TLISTalis Biomedical Corporation
23/05/202309:00GlobeNewswire Inc.Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent DirectorNASDAQ:TLISTalis Biomedical Corporation
11/05/202317:05GlobeNewswire Inc.Talis Biomedical Announces Business Update and First Quarter 2023 Financial ResultsNASDAQ:TLISTalis Biomedical Corporation
04/05/202309:00GlobeNewswire Inc.Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023NASDAQ:TLISTalis Biomedical Corporation
28/04/202317:20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TLISTalis Biomedical Corporation
28/04/202317:15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TLISTalis Biomedical Corporation
22/03/202317:05GlobeNewswire Inc.Talis Announces Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:TLISTalis Biomedical Corporation
10/03/202318:56Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:TLISTalis Biomedical Corporation
10/03/202318:31Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TLISTalis Biomedical Corporation
15/02/202308:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TLISTalis Biomedical Corporation
16/11/202204:57TipRanksTalis Biomedical (TLIS) Gets a Sell from BTIGNASDAQ:TLISTalis Biomedical Corporation
03/11/202217:05GlobeNewswire Inc.Talis Biomedical Reports Third Quarter 2022 Financial ResultsNASDAQ:TLISTalis Biomedical Corporation
02/08/202217:05GlobeNewswire Inc.Talis Biomedical Provides Business Update and Reports Second Quarter Financial ResultsNASDAQ:TLISTalis Biomedical Corporation
24/05/202217:26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:TLISTalis Biomedical Corporation
12/05/202204:45TipRanksBTIG Sticks to Its Sell Rating for Talis Biomedical (TLIS)NASDAQ:TLISTalis Biomedical Corporation
10/05/202217:05GlobeNewswire Inc.Talis Biomedical Announces First Quarter 2022 Financial ResultsNASDAQ:TLISTalis Biomedical Corporation
26/04/202209:00GlobeNewswire Inc.Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022NASDAQ:TLISTalis Biomedical Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:TLIS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AMER3
Americanas ON
BOV
GOLL4
GOL PN
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados